SNDL Inc.

NASDAQ:SNDL

Drug Manufacturers - Specialty & Generic

Healthcare
$1.34 -1.74%

-$0.03 today

Market cap
$326.64M
Beta
0.91
P/E (TTM)
-47.4
EPS (TTM)
-$0.04
52W Low $1.15High $2.89

Volume 1.00M

Average 2.21M

SNDL Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

SNDL Inc.NASDAQ: SNDL

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of CA$51.23M fell 0.5% year over year, ahead of the -3.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 9.1% from the prior quarter. Over 3 fiscal years it compounded at +10.0% a year.

Context

  • Selling, general & admin amounted to 22.3% of revenue in FY2025, down 1.6 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 2 analysts of CA$351.29M (+66.8%) for the fiscal year ending Dec 2026, a step up from the -3.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$51.23M+9.1% QoQ
Last fiscal yearDec 2025
CA$210.63M-3.9% YoY
LTMMar 2026
CA$210.35M-3.8% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.5%+75.8%+76.4 pp
1 year-3.9%+66.8%+70.7 pp
3-year CAGR+10.0%+15.6%+5.6 pp
5-year CAGR+10.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

CAD · from the income statement

Latest · FY2025
210.63M CAD
Year-over-year change
-3.9%
4-year CAGR
+39.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How SNDL compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -3.8% is the 9th highest of 11, against a peer median of +15.4%.
  • Selling, general & admin amounts to 22.4% of revenue for SNDL, versus a peer median of 62.1%.
SNDL Competitors
Selling, General & Admin for SNDL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SIGASIGA Technologies, Inc.LTM Mar 2026$4.67T USD+20374087.6%-55.3%4982813.7%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$318.91M USD+8.2%+4.8%62.1%
EOLSEvolus, Inc.LTM Mar 2026$216.13M USD+3.1%+15.9%71.6%
SNDLSNDL Inc.LTM Mar 2026CA$210.35M CAD-3.8%+10.0%22.4%
EBSEmergent BioSolutions Inc.LTM Mar 2026$180.5M USD-32.3%-18.1%26.7%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$165.91M USD+1.1%+15.0%39.7%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$113.07M USD+41.5%-8.1%48.7%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$71.75M USD+22.5%+14.7%142.7%
CMPSCOMPASS Pathways plcLTM Mar 2026$58.26M USD-9.3%+10.1%—
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$25.39M USD+44.8%-5.3%—
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$10.49M USD+24.0%+4.5%—
Peer median (excluding SNDL) —+15.4%+4.6%62.1%

Competitors are the stored peer set for SNDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue56.13M712.2M909.01M920.45M946.4M
Cost of Revenue65.13M571.82M718.59M680.12M687.75M
Gross Profit(9M)140.38M190.42M240.33M258.65M
Gross Margin-16.0%19.7%20.9%26.1%27.3%
Research & Development2.45M2.45M324K346K489K
Selling, General & Admin55.39M158.26M230.17M219.28M210.63M
Operating Expenses125.38M488.15M353.59M344.14M263.07M
Depreciation & Amortization10.16M47.32M64.95M56.71M56.27M
EBITDA(223.76M)(326.55M)(99.15M)(41.2M)48.02M
EBITDA Margin-398.7%-45.9%-10.9%-4.5%5.1%
Operating Income(134.38M)(347.77M)(163.17M)(103.81M)(4.42M)
Operating Margin-239.4%-48.8%-18.0%-11.3%-0.5%
Interest Income13.72M17.62M15.37M16.4M8.05M
Interest Expense776K5.9M7.92M7.7M7.52M
Other Income / Expenses(100.32M)(32M)(8.85M)(1.8M)(11.35M)
Income Before Tax(234.7M)(379.77M)(172.02M)(105.61M)(15.77M)
Pre-Tax Margin-418.1%-53.3%-18.9%-11.5%-1.7%
Income Tax Expense(7.91M)(7.34M)0(9.41M)0
Net Income(226.98M)(335.11M)(172.66M)(94.8M)(15.77M)
Net Margin-404.4%-47.1%-19.0%-10.3%-1.7%
EPS (Basic)(1.24)(1.50)(0.65)(0.38)(0.06)
EPS (Diluted)(1.24)(1.50)(0.65)(0.38)(0.06)
Weighted Avg Shares186.04M229.87M259.37M264.2M258.05M
Weighted Avg Shares (Diluted)186.04M229.87M259.37M264.2M258.05M

SNDL Inc.

NASDAQ:SNDL

Intrinsic Alpha fair value

Locked

Current Price

$1.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.